AN2 Therapeutics (ANTX) Cash from Operations (2021 - 2026)
AN2 Therapeutics (ANTX) reported Cash from Operations of 12073000.0 for Q1 2026, down 13.64% year-over-year from 13979678.69 in Q1 2025, and down 130.66% quarter-over-quarter from 5234000.0 in Q4 2025.
AN2 Therapeutics (ANTX) Cash from Operations (2021 - 2026) Analysis & Trends
AN2 Therapeutics (ANTX) has 6 years of Cash from Operations data on file, last reported at 12073000.0 in Q1 2026.
- Cash from Operations for Q1 2026 came in at 12073000.0, down 13.64% year-over-year; the trailing twelve-month figure through Mar 2026 was 31283000.0 (up 26.02% YoY), and the FY2025 annual result was 29834000.0, up 39.43% from the prior year.
- Cash from Operations retreated to 12073000.0 in Q1 2026 per ANTX's latest filing, from 5234000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 5234000.0 in Q4 2025 and troughed at 17593000.0 in Q1 2024.
- A 5-year average of 10465529.41 and a median of 10624000.0 in 2025 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2022 and 2024: Cash from Operations tumbled 336.94% in 2022, then surged 69.24% in 2024.
- A 5-year view of Cash from Operations shows it stood at 7638000.0 in 2022, then tumbled by 123.72% to 17088000.0 in 2023, then surged by 69.24% to 5257000.0 in 2024, then gained by 0.44% to 5234000.0 in 2025, then tumbled by 130.66% to 12073000.0 in 2026.
- Business Quant data shows ANTX's Cash from Operations at 12073000.0 in Q1 2026, 5234000.0 in Q4 2025, and 6400000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -2.49 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | AN2 Therapeutics | 161.95 Mn | 161.95 Mn | - | -12.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -12.07 Mn |
| Mar 31, 2026 | -12.07 Mn |
| Dec 31, 2025 | -5.23 Mn |
| Dec 31, 2025 | -5.23 Mn |
| Sep 30, 2025 | -6.40 Mn |
| Sep 30, 2025 | -6.40 Mn |
| Jun 30, 2025 | -7.58 Mn |
| Jun 30, 2025 | -7.58 Mn |
| Mar 31, 2025 | -10.62 Mn |
| Mar 31, 2025 | -10.62 Mn |
| Dec 31, 2024 | -5.26 Mn |
| Dec 31, 2024 | -5.26 Mn |
| Sep 30, 2024 | -12.02 Mn |
| Sep 30, 2024 | -12.02 Mn |
| Jun 30, 2024 | -14.38 Mn |
| Jun 30, 2024 | -14.38 Mn |
| Mar 31, 2024 | -17.59 Mn |
| Mar 31, 2024 | -17.59 Mn |
| Dec 31, 2023 | -17.09 Mn |
| Dec 31, 2023 | -17.09 Mn |